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Few ATLL cases have been reported in the country, the
majority of the acute leukemia subtype. HTLV-1 proviral
load is considered a prognosis marker and it has been
available in our setting since 2008. We present HTLV-1
proviral loads in 3 cases of ATLL received during the last
4 years. Two cases were of the acute subtype and one
case of the lymphoma subtype. All were male with ages
of 49, 34 and 54, respectively at diagnosis. Both acute
cases were treated with CHOP chemotherapy. One was
responder and one was chemo resistant. The latter after
several treatments had disease progression and died
16 months after diagnosis. HTLV-1 proviral load was
only measured at 10 months from diagnosis and was
5.3 log10/106 PBMC. The acute responder case had sev-
eral measures of proviral load after clinical remission
post-CHOP and during antiretroviral treatment plus
alpha interferon. The proviral load was high but stable
during almost four years (5.36 log10/106 PBMC). After-
wards, the patient was stopping treatment with inter-
feron. Proviral load was 5.16 log10/106 PBMC and
6 log10/106 PBMC after one and 6 months, respectively.
The lymphoma case was recently diagnosed (February
2013) had a proviral load of 3,76 log10/106 PBMC at that
time and is currently untreated. The two acute leukemia
cases showed similarly high proviral loads despite differ-
ences in survival time and response to treatment. Other-
wise, in the lymphoma case proviral load was lower than
in the acute leukemia cases. Further proviral load studies
are needed to confirm this preliminary finding.
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